Clinical Trials Browser

OTHER × Interventional × Immune System Diseases × Clear all

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT03602157 2026-01-06

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Phase 1 Active not recruiting

43 enrolled

DermatologicLymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Mycosis Fungoides, Neoplasms, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphomatoid Papulosis

NCT03696784 2025-12-08

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Phase 1 Active not recruiting

19 enrolled

Lymphoid

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, B-Cell, Neurotoxicity Syndromes

NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Phase 1/2 Active not recruiting

17 enrolled

LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05963217 2025-07-02

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Phase 1 Recruiting

19 enrolled

LymphoidOther hematologic neoplasm

Immune System Diseases, Lymphoma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02663297 2025-05-15

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

Phase 1 Active not recruiting

18 enrolled 10 charts

Lymphoid

Hodgkin Disease, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type

NCT06644443 2024-10-16

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Phase 1/2 Recruiting

10 enrolled

LymphoidPlasma cell

Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, Hemorrhagic Disorders, Immune System Diseases, Immunoproliferative Disorders, Lymphoproliferative Disorders, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Vascular Diseases, Hemostatic Disorders, Neoplasms, Plasma Cell

NCT04097067 2024-08-27

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

Phase NA Recruiting

83 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT03349450 2023-11-02

SPiReL

Phase 2 Completed

25 enrolled

LymphoidSarcoma

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Recurrence, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Dendritic Cell Sarcoma, Interdigitating

NCT06065592 2023-10-06

CAT_PB

Phase 1 Unknown

500 enrolled

BreastGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Cardiovascular Diseases, Colonic Neoplasms, Carcinoma, Hepatocellular, Immune System Diseases, Inflammation, Lung Neoplasms, Neoplasms, Prostatic Neoplasms, Thromboembolism, Thrombosis

NCT04258683 2023-08-29

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

Phase 2 Withdrawn

Plasma cell

Cardiovascular Diseases, Hematologic Diseases, Immune System Diseases, Multiple Myeloma, Neoplasms

NCT02799147 2020-11-23

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

Phase 1/2 Completed

27 enrolled

LymphoidOther hematologic neoplasm

Immune System Diseases, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02519816 2019-08-14

CARE

Phase 2 Unknown

17 enrolled

Immune System Diseases

NCT02670564 2019-04-16

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Phase 4 Recruiting

1,000 enrolled

LymphoidOther hematologic neoplasm

Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Lymphoid, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02627573 2019-04-05

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Phase 2 Terminated

32 enrolled

MyeloidOther hematologic neoplasm

Immune System Diseases, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative

NCT02294552 2018-01-16

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Phase 2 Completed

200 enrolled

LymphoidMyeloidOther hematologic neoplasm

Immune System Diseases, Leukemia, Lymphoma, Myelodysplastic Syndromes, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT03373019 2017-12-14

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

Phase 2 Unknown

63 enrolled

Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT02765594 2017-09-20

HCQIgAN

Phase 4 Unknown

98 enrolled

Genitourinary

Autoimmune Diseases, Glomerulonephritis, Glomerulonephritis, IGA, Immune System Diseases, Kidney Diseases, Nephritis, Urologic Diseases

NCT02134262 2014-11-06

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes

Phase 1/2 Unknown

18 enrolled

Lymphoid

Burkitt Lymphoma, Immune System Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphomatoid Granulomatosis, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Experimental, Recurrence, Lymphoma, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Lymphoma, Extranodal NK-T-Cell

Clinical Trials

Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL

Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL

Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Administration of T Lymphocytes for Prevention of Relapse of Lymphomas

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma

SPiReL

CAT_PB

A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

CARE

ALL SCTped FORUM - Pharmacogenomic Study (add-on Study)

Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT

Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)

HCQIgAN

Gene Therapy for B-Cell Non-Hodgkin Lymphoma Using CD19 CAR Gene Transduced T Lymphocytes